SOMA Médical, a subsidiary of Groupe Vicenne specializing in implantable medical devices, has introduced MitraClip in Morocco. Developed by Abbott, MitraClip is a solution for managing certain patients with mitral insufficiency. This minimally invasive approach acts directly on the valve to reduce blood reflux without requiring open-heart surgery. It is particularly considered for patients with a high risk associated with conventional cardiac surgery.
Mitral insufficiency occurs when the valve between the left atrium and left ventricle does not close properly. As a result, some blood flows back into the atrium with each heartbeat. MitraClip is delivered to the heart using a catheter inserted through a vein. The device brings the mitral valve leaflets together to improve closure and reduce blood leakage. The procedure does not require opening the thorax or stopping the heart.
Compared to open-heart surgery, this technique may allow for shorter hospitalization and faster recovery. Results depend on the patient's clinical condition and medical profile. Over 200,000 patients worldwide have been treated with MitraClip, which employs the Transcatheter Edge-to-Edge Repair (TEER) technique. Several generations of the device have been developed, with different configurations enabling medical teams to adapt the procedure to the valve's anatomical characteristics.
In Morocco, this technique can now be considered among therapeutic options for eligible patients, following evaluation by a multidisciplinary medical team. The introduction of MitraClip in Morocco is part of the partnership between SOMA Médical and Abbott, which focuses on making medical technologies available and integrating them into healthcare practices in Morocco.
The first percutaneous mitral repair procedure using MitraClip in Morocco was performed on September 20 at the Hôpital Privé International de Casablanca (HPIC), owned by the CIM Santé group. The procedure involved a multidisciplinary medical team and used the TEER technique. This development highlights the advancements in cardiac care available in Morocco.
MitraClip's introduction in Morocco expands treatment options for patients with mitral insufficiency, particularly those at high risk for traditional surgery. The device's effectiveness and safety have been demonstrated in various clinical settings worldwide. As the healthcare landscape in Morocco continues to evolve, the availability of innovative treatments like MitraClip is expected to positively impact patient outcomes.
The partnership between SOMA Médical and Abbott underscores the commitment to enhancing healthcare services in Morocco. By providing access to cutting-edge medical technologies, patients in Morocco can benefit from the latest advancements in treatment options. This collaboration is set to improve the quality of care for patients with cardiovascular conditions.
Key points
- MitraClip has been used to treat over 200,000 patients worldwide.
- The procedure does not require open-heart surgery.
- MitraClip is a product of the partnership between SOMA Médical and Abbott.
